Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: Randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection

Andre S. Nell, Eva D'Lom, Patrick Bouic, Montserrat Sabaté, Ramon Bosser, Jordi Picas, Mercè Amat, Gavin Churchyard, Pere Joan Cardona

Research output: Contribution to journalArticleResearchpeer-review

57 Citations (Scopus)

Fingerprint Dive into the research topics of 'Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: Randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection'. Together they form a unique fingerprint.

Agriculture & Biology

Medicine & Life Sciences

Chemical Compounds